References
[1] Wang JQ, Lan L, Ma B, et al. KRT17 accelerates cell proliferative and invasive potential of laryngeal squamous cell carcinoma through regulating AKT/mTOR and Wnt/β-catenin pathways. Evid Based Complement Alternat Med. 2022;2022:6176043.
[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
[3] Cavaliere M, Bisogno A, Scarpa A, et al. Biomarkers of laryngeal squamous cell carcinoma: a review. Ann Diagn Pathol. 2021;54:151787.
[4] Jiang X, Jiang W. The construction and validation of ECM-related prognosis model in laryngeal squamous cell carcinoma. Heliyon. 2023;9(9):e19907.
[5] Dai F, Xie Z, Yang Q, et al. MicroRNA-375 inhibits laryngeal squamous cell carcinoma progression via targeting CST1. Braz J Otorhinolaryngol. 2022;88(Suppl 4):S108-16.
[6] Zhao R, Yang Z, Zhao B, et al. A novel tyrosine tRNA-derived fragment, tRFTyr, induces oncogenesis and lactate accumulation in LSCC by interacting with LDHA. Cell Mol Biol Lett. 2023;28(1):49.
[7] Xia L, Oyang L, Lin J, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20:1-21.
[8] Cronin SJF, Seehus C, Weidinger A, et al. The metabolite BH4 controls T cell proliferation in autoimmunity and cancer. Nature. 2018;563(7732):564-8.
[9] Oliveira LM, Teixeira FME, Sato MN. Impact of retinoic acid on immune cells and inflammatory diseases. Mediators Inflamm. 2018;2018:3067126.
[10] Sturm G, Finotello F, Petitprez F, et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immunooncology. Bioinformatics. 2019;35(14):i436-45.
[11] Shen Y, Huang Q, Zhang Y, et al. A novel signature derived from metabolism-related genes GPT and SMS to predict prognosis of laryngeal squamous cell carcinoma. Cancer Cell Int. 2022;22(1):226.
[12] Hong X, Li Y, Lv Q, et al. Identification of an immune-related genes signature to predict risk of recurrence for patients with laryngeal squamous cell carcinoma. Int J Immunopathol Pharmacol. 2023;37:03946320231172075.
[13] Fountzilas E, Markou K, Vlachtsis K, et al. Identification and validation of gene expression models that predict clinical outcome in patients with early-stage laryngeal cancer. Ann Oncol. 2012;23(8):2146-53.
[14] Huang H, Zhou S, Zhao X, et al. Construction of a metabolism-related gene prognostic model to predict survival of pancreatic cancer patients. Heliyon. 2023;9(1):e12378.
[15] Wu P, Sun W, Zhang H. An immune-related prognostic signature for thyroid carcinoma to predict survival and response to immune checkpoint inhibitors. Cancer Immunol Immunother. 2022;71(3):747-59.
[16] Geeleher P, Cox NJ, Huang RS. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol. 2014;15:R47.
[17] Li JD, Chen Y, Jing SW, et al. Triosephosphate isomerase 1 may be a risk predictor in laryngeal squamous cell carcinoma: a multi-centered study integrating bulk RNA, single-cell RNA, and protein immunohistochemistry. Eur J Med Res. 2023;28(1):591.
[18] Chuang YM, Tzeng SF, Ho PC, et al. Immunosurveillance encounters cancer metabolism. EMBO Rep. 2024;25(2):471-88.
[19] Mukhopadhyay TK, Trauner D. Concise synthesis of glycerophospholipids. J Org Chem. 2022;88(15):11253-7.
[20] Dolce V, Cappello AR, Lappano R, et al. Glycerophospholipid synthesis as a novel drug target against cancer. Curr Mol Pharmacol. 2011;4(3):167-75.
[21] Perrotti F, Rosa C, Cicalini I, et al. Advances in lipidomics for cancer biomarkers discovery. Int J Mol Sci. 2016;17(12):1992.
[22] Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393-8.
[23] Valković T, Dobrila F, Melato M, et al. Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch. 2002;440:583-8.
[24] Shieh YS, Hung YJ, Hsieh CB, et al. Tumor-associated macrophage correlated with angiogenesis and progression of mucoepidermoid carcinoma of salivary glands. Ann Surg Oncol. 2009;16:751-60.
[25] Deryugina EI, Quigley JP. Tumor angiogenesis: MMP-mediated induction of intravasation-and metastasis-sustaining neovasculature. Matrix Biol. 2015;44:94-112.
[26] Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018;15(5):310-24.
[27] Chung AS, Wu X, Zhuang G, et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med. 2013;19(9):1114-23.
[28] Shrimali RK, Yu Z, Theoret MR, et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70(15):6171-80.
[29] Wallin JJ, Bendell JC, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in meta-static renal cell carcinoma. Nat Commun. 2016;7:12624.
[30] Wang F, Jin Y, Wang M, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nat Med. 2024;30(4):1035-43.
[31] Huang Q, Ji M, Li F, et al. Diagnostic and prognostic value of plasma cell-free DNA combined with VEGF-C in laryngeal squamous cell carcinoma. Mol Cell Probes. 2023;67:101895.
[32] Schlüter A, Weller P, Kanaan O, et al. CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma. BMC Cancer. 2018;18(1):272.
[33] Zhang T, Liu M, Wang C, et al. Down-regulation of MiR-206 promotes proliferation and invasion of laryngeal cancer by regulating VEGF expression. Anticancer Res. 2011;31(11):3859-63.
[34] Niu F, Yu Y, Li Z, et al. Arginase: An emerging and promising therapeutic target for cancer treatment. Biomed Pharmacother. 2022;149:112840.
[35] Giatromanolaki A, Harris AL, Koukourakis MI. The prognostic and therapeutic implications of distinct patterns of argininosuccinate synthase 1 (ASS1) and arginase-2 (ARG2) expression by cancer cells and tumor stroma in non-small-cell lung cancer. Cancer Metab. 2021;9(1):28.
[36] Grzywa TM, Sosnowska A, Matryba P, et al. Myeloid cell-derived arginase in cancer immune response. Front Immunol. 2020;11:938.
[37] Bron L, Jandus C, Andrejevic-Blant S, et al. Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma. Int J Cancer. 2013;132(3):E85-93.
[38] Giannoudis A, Varešlija D, Sharma V, et al. Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression. ESMO Open. 2022;7(6):100636.
[39] Tang Y, Xu L, Ren Y, et al. Identification and validation of a prognostic model based on three MVI-related genes in hepatocellular carci-noma. Int J Biol Sci. 2022;18(1):261-75.
[40] Zhang J, Jin Y, Xu S, et al. AGR2 is associated with gastric cancer progression and poor survival. Oncol Lett. 2016;11(3):2075-83.
[41] Weis-Banke SE, Lisle TL, Perez-Penco M, et al. Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells. J Immunother Cancer. 2022;10(10):e005326.
[42] Tao P, Han X, Wang Q, et al. A gain-of-function variation in PLCG1 causes a new immune dysregulation disease. J Allergy Clin Immunol. 2023;152(5):1292-302.
[43] Sun M, Chen S, Fu M. Model establishment of prognostic-related immune genes in laryngeal squamous cell carcinoma. Medicine (Balti-more). 2021;100(2):e24263.
[44] Zhu D, Tan Y, Yang X, et al. Phospholipase C gamma 1 is a potential prognostic biomarker for patients with locally advanced and resec-table oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2014;43(12):1418-26.
[45] Shiseki M, Ishii M, Miyazaki M, et al. Reduced PLCG1 expression is associated with inferior survival for myelodysplastic syndromes. Cancer Med. 2020;9(2):460-8.
[46] Tremblay-Laganière C, Michaud C, Abourjaili-Bilodeau R, et al. Homozygous variant in TKFC abolishing triokinase activities is associated with isolated immunodeficiency. J Med Genet. 2024.
[47] Mu M, Niu W, Chu F, et al. CircSOBP suppresses the progression of glioma by disrupting glycolysis and promoting the MDA5-mediated immune response. iScience. 2023;26(10):107897.
[48] Walakira A, Skubic C, Nadižar N, et al. Integrative computational modeling to unravel novel potential biomarkers in hepatocellular carcinoma. Comput Biol Med. 2023;159:106957.